Improving how we diagnose skin cancer

Background

We supported a clinical study funded by the Skin Cancer College of Australasia exploring the use of microbiopsy to identify biomarkers for BCC. As a minimally invasive diagnostic tool, the novel device provides a less painful and more efficient alternative to traditional biopsy methods for detecting and understanding BCC.

‍

Objective

To validate the use of a novel microbiopsy device in clinical settings for identifying biomarkers associated with BCC, improving potential for early diagnosis and overall patient experience.

‍

Approach

Leveraging extensive early-stage clinical trial expertise, we:

• provided strategic input on study design to ensure robust data collection and alignment with regulatory requirements
• facilitated the practical application of microbiopsy techniques in a real-world clinical setting, addressing logistical challenges
• guided the evaluation of the microbiopsy method, assessing efficiency, patient tolerability and diagnostic potential.

Results

• Successful trialling of the microbiopsy technique in 106 patients, and demonstration of its feasibility and reliability.
• Identification of biomarkers for BCC, and the delivery of valuable data for early diagnosis and treatment strategies.
• Validation of microbiopsy as a minimally invasive, acceptable alternative to traditional biopsy methods, offering reduced pain and faster sampling.

Key takeaways

• Our guidance ensured the study successfully demonstrated the diagnostic potential of the microbiopsy device.
• Minimally invasive methods such as this can improve patient compliance and diagnostic efficiency, revolutionizing skin cancer care.
• The study reinforced our ability to navigate complex trial logistics while implementing innovative healthcare solutions.